Celanese Corporation (CE) recently announced the launch of Glaukos Corporation's iDose TR. This uses CE's VitalDose EVA to offer continuous medication release for the treatment of glaucoma.The majority of glaucoma and ocular hypertension patients do not adhere to topical drug regimens due to complex dosing courses, adverse effects and eye-drop sensitivity. Sustained delivery of medications is a significant technique for addressing noncompliance and enhancing treatment results. With iDose TR and VitalDose EV ...

DALLAS--(BUSINESS WIRE)--Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, announced the launch of iDose® TR by Glaukos Corporation using Celanese’s VitalDose® EVA to provide sustained drug release for the treatment of glaucoma. The majority of glaucoma and ocular hypertension patients are non-compliant with topical medication use due to complex dosing regiments, side effects, and eye-drop intolerance. Sustained delivery of therapeutics provides an important approach in ...

DALLAS--(BUSINESS WIRE)--Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today announced that Timothy Go has been elected to the company’s Board of Directors. Mr. Go, 57, is President, Chief Executive Officer, and a member of the Board of Directors of HF Sinclair Corporation. He will begin his Board service effective immediately, bringing the total number of Board members to twelve (eleven of which are independent). HF Sinclair Corporation is a leading independent energy ...

While companies who rank among the earnings losers category don’t obviously generate confidence, it’s also important to keep in mind the big picture. Technology juggernaut Nvidia (NASDAQ:NVDA) provides an extreme example of this.In the third quarter of 2023, Nvidia posted earnings per share of 58 cents. This tally represented a stinker against the estimated EPS target of 70 cents. The company took it personally. Since then, the company has been beating its targets, continuing to impress onlookers up until t ...

We have a structured approach to reviewing talent with management, as well as with the Board of Directors. This includes discussions of employee development, executive succession, diversity, talent pipelines and workforce planning requirements. We regularly report to the Board of Directors on talent management strategies across functional areas, and annually review executive succession with the Board of Directors. Available Information — Securities and Exchange Commission ("SEC") Filings and Corporate Gover ...

业绩总结 - 首席执行官Lori Ryerkerk表示，预计第一季度M&M业务的收益将有显著提升，预计将是收购以来最高的季度EBITDA[12] - 预计2024年原材料成本将保持稳定，公司将继续专注于可控制的因素，并利用在2023年的执行力[21] - 预计M&M业务的协同效应为1.5亿美元，其中约40%体现在M&M业务中[25] - 预计M&M业务在2024年将实现EBIT增长，不包括协同效应[27] - 预计剩余三个季度的每个季度EBIT为3亿至3.4亿美元[31] - 公司预计2024年的销售需求模式将低于正常水平，但不包括去库存[37] - 公司预计2024年第二季度将有显著增长，第三季度和第四季度将有更大的增长[32] - 2023年实现了1亿美元的协同效益，略低于预期，但仍高于年初预期[52] - 醋酸盐业务表现出色，预期收益大幅超出目标，对整个醋酸盐链的稳定收益起到了积极作用[54][55] - 公司对汽车建设的预期为基本持平，对混合动力车型的需求增长持乐观态度[58] - 预计2024年醋酸盐业务的基础收益将增加1亿美元，达到13亿美元[63][64] - 预计2024年税率将保持在9%左右，公司认为目前的税率处于良好位置[68] - 2024年的自由现金流关键驱动因素包括盈利、营运资本和资本支出[73] - 目标是在2025年达到3倍杠杆比率[74] - 在2023年，公司通过减少库存约4.5亿美元，其中80%来自EM，对EBITDA产生了负面影响[89] - 中国醋酸定价在整个年份内保持稳定，除了在第三季度末因行业停产而出现短暂上涨，但很快在第四季度消失[96] - 中国醋酸产能增加，但已被吸收，利用率仍在85%至90%之间，预计2024年的产能增加对价格不会产生长期影响[96] - 全球供应链的价值得到体现，尽管红海和苏伊士运河出现挑战，但由于公司的全球供应链，能够从世界其他地区提供产品，因此不会受到增加成本的影响[98] - 公司认为汽车制造商减少库存对公司影响不大，因为低库存已经在当前情况下得到体现，未来不会对公司产生显著影响[101] - Clear Lake醋酸扩张项目的100百万美元生产力提升是合理的，同时也与CCU项目相关，这对公司的长期EBITDA潜力有积极影响[103] - Clear Lake项目的扩张不仅提高了公司在美国墨西哥湾岸的冗余能力，还能够在未来更好地应对该地区的突发情况[105] - 由于中国市场需求减少，亚洲POM产品出口到欧洲减少，这可能与红海事件有关，同时也显示了亚洲市场的增强[109] - Vamac橡胶的库存周期较难追踪，由于其在汽车领域的独特属性和市场定位，公司对其未来项目有着积极的展望[111] - 公司自收购以来，成功解决了可靠性问题并增加了生产，使得客户购买量稳定[112] - M&M业务中，尼龙和亚洲业务出现了收入短缺，主要是在标准级别尼龙和在2022年由于定价决策而丢失的销量[114][116][118] - 醋酸价值链上游的需求与供应压力可能会对今年产生影响，公司计划在中游或下游推动以获取更多市场份额[115][120] - 预计今年第一季度将有5000万美元的影响，而在接下来的三个季度也会有类似的影响，但与去年相比是一致的[123][124]

Celanese Corporation (CE) reported fourth-quarter 2023 earnings from continuing operations of $6.43 per share, down 8.5% from $7.03 reported in the prior-year quarter.Adjusted earnings in the fourth quarter were $2.24 per share, up from $1.44 reported in the prior year. It lagged the Zacks Consensus Estimate of $2.29.Revenues of $2,569 million increased roughly 9.4% year over year but missed the Zacks Consensus Estimate of $2,610.6 million.Segment HighlightsNet sales in the Engineered Materials unit were $1 ...

财报表现 - Celanese (CE)在2023年12月结束的季度报告中，营收达到25.7亿美元，同比增长9.4%[1] - 同期每股收益为2.24美元，相比去年的1.44美元有所增长[1] - 公司的营收表现低于Zacks Consensus Estimate的2.61亿美元，营收惊喜为-1.59%；而每股收益也低于预期的2.29美元，EPS惊喜为-2.18%[2] 重要指标比较 - Celanese在最近报告的季度中，在华尔街分析师广泛关注的指标方面表现如下： - Acetyl Chain净销售额：11.8亿美元，高于六位分析师平均预估的11.4亿美元，同比增长4.1%[5] - Inter segment eliminations净销售额：-1800万美元，低于六位分析师平均预估的-2405万美元，同比下降25%[6] - Engineered Materials净销售额：14.1亿美元，低于六位分析师平均预估的14.9亿美元，同比增长13.7%[7] - Acetyl Chain运营EBITDA：3.54亿美元，低于五位分析师的平均预估3632.9万美元[8] - Engineered Materials运营EBITDA：3.11亿美元，高于五位分析师的平均预估3088.3万美元[9] - 其他活动运营EBITDA：-5700万美元，低于四位分析师的平均预估-9093万美元[10] 股票表现 - Celanese股票在过去一个月中表现良好，涨幅为+4%，目前具有Zacks Rank 2（买入），表明在短期内可能会跑赢整个市场[11]

Celanese (CE) came out with quarterly earnings of $2.24 per share, missing the Zacks Consensus Estimate of $2.29 per share. This compares to earnings of $1.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.18%. A quarter ago, it was expected that this chemical company would post earnings of $2.20 per share when it actually produced earnings of $2.50, delivering a surprise of 13.64%.Over the last four quarters, the company ...

Celanese (CE)财报预测 - Celanese (CE)预计在即将发布的季度报告中，每股盈利将达到2.29美元，同比增长59%[1] - 预计营收将达到26.1亿美元，同比增长11.2%[1] 销售预测 - 分析师们一致认为，'Net Sales- Acetyl Chain'将达到11.4亿美元，同比增长+0.3%[6] - 'Net Sales- Engineered Materials'的一致预测为14.9亿美元，同比增长+20.3%[7] EBITDA预测 - 分析师们预测'Operating EBITDA- Acetyl Chain'将达到3.6329亿美元，较去年同期的2.94亿美元有所增长[8] - 'Operating EBITDA- Engineered Materials'的平均预测为3.0883亿美元，较去年同期的2.28亿美元有所增长[8]